VETINUITY
FDA shortage status details for clindamycin injection, including manufacturer availability and supply dates.
The FDA lists clindamycin phosphate injection in shortage, with Pfizer presentations currently unavailable due to manufacturing delays while Baxter and Sandoz formulations remain Available.
Clindamycin: human-labeled FDA records matched to our veterinary drug catalog.
| FDA field | Product-specific value |
|---|---|
| Record 1 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9545-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0338-9545-50 |
| Record 2 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-9553-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0338-9553-50 |
| Record 3 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-9549-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Limited Availability |
| FDA additional information | Estimated recovery: November 2026 |
| Package NDC | 0338-9549-50 |
| Record 4 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 0781-3289-09) |
| Company | Sandoz Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/09/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0781-3289-09 |
| Record 5 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Cleocin Phosphate, Injection, Cleocin Phosphate 600 mg/4 mL (150 mg/mL) (NDC 0009-0775-26) |
| Company | Pfizer Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Unavailable |
| FDA additional information | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay |
| Package NDC | 0009-0775-26 |
| Record 6 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-02) |
| Company | Sagent Pharmaceuticals |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Limited Availability |
| FDA additional information | Selling through remaining short-dated inventory (Dec 2026). |
| Package NDC | 25021-115-02 |
| Record 7 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 300 mg/50 mL (NDC 0338-3410-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0338-3410-50 |
| Record 8 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-04) |
| Company | Sagent Pharmaceuticals |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Unavailable |
| FDA additional information | Discontinuation of the manufacture of the drug |
| Package NDC | 25021-115-04 |
| Record 9 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 900 mg/50 mL (NDC 0338-3814-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Unavailable |
| FDA additional information | Estimated recovery: January 2027 |
| Package NDC | 0338-3814-50 |
| Record 10 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 12 mg/1 mL (NDC 72572-074-24) |
| Company | Sandoz Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/09/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Civica Label |
| Package NDC | 72572-074-24 |
| Record 11 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 6 mg/1 mL (NDC 0781-3288-09) |
| Company | Sandoz Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/09/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0781-3288-09 |
| Record 12 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 150 mg/1 mL (NDC 25021-115-06) |
| Company | Sagent Pharmaceuticals |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Limited Availability |
| FDA additional information | Selling through remaining short-dated inventory (Dec 2026). |
| Package NDC | 25021-115-06 |
| Record 13 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate, Injection, 600 mg/50 mL (NDC 0338-3612-50) |
| Company | Baxter Healthcare |
| First posted | 03/21/2023 |
| FDA updated | 11/03/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0338-3612-50 |
| Record 14 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 72572-076-24) |
| Company | Sandoz Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/09/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Civica Label |
| Package NDC | 72572-076-24 |
| Record 15 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Clindamycin Phosphate In 5% Dextrose In Plastic Container, Injection, 18 mg/1 mL (NDC 0781-3290-09) |
| Company | Sandoz Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/09/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Available |
| FDA additional information | Not stated |
| Package NDC | 0781-3290-09 |
| Record 16 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Cleocin Phosphate, Injection, Cleocin Phosphate 900 mg/6 mL (150 mg/mL) (NDC 0009-0902-18) |
| Company | Pfizer Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Unavailable |
| FDA additional information | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay |
| Package NDC | 0009-0902-18 |
| Record 17 | Clindamycin Phosphate Injection |
| FDA generic name | Clindamycin Phosphate Injection |
| FDA shortage status | Current |
| Dosage form | Injection |
| Presentation | Cleocin Phosphate, Injection, Cleocin Phosphate 300 mg/2 mL (150 mg/mL) (NDC 0009-0870-26) |
| Company | Pfizer Inc. |
| First posted | 03/21/2023 |
| FDA updated | 11/06/2026 |
| Resolved date | Not stated |
| Discontinued date | Not stated |
| Human therapeutic category | Anti-Infective |
| Presentation availability | Unavailable |
| FDA additional information | Next Delivery and Estimated Recovery: December 2028; Shortage per Manufacturer: Manufacturing Delay |
| Package NDC | 0009-0870-26 |
In dogs diagnosed with Neospora caninum infection, treatment with clindamycin and potentiated sulphonamides may be useful when muscular atrophy and fibrosis are absent. For small form canine Babesia species such as Babesia gibsoni, the combination of atovaquone and azithromycin is used, whereas a triple combination of clindamycin, diminazene aceturate, and imidocarb dipropionate is used for atovaquone-resistant B. gibsoni strains.
The FDA lists clindamycin phosphate injection in shortage. Stock status varies across specific presentations: Pfizer Inc. has Cleocin Phosphate 300 mg/2 mL, 600 mg/4 mL, and 900 mg/6 mL presentations listed as Unavailable due to manufacturing delays with manufacturer-estimated recovery dates of December 2028. Sagent Pharmaceuticals lists 150 mg/1 mL NDC 25021-115-04 as Unavailable due to discontinuation of manufacture, while NDCs 25021-115-02 and 25021-115-06 are Limited Availability, selling through remaining short-dated inventory through December 2026.
Conversely, Baxter Healthcare lists 300 mg/50 mL, 600 mg/50 mL, and 900 mg/50 mL presentations as Available, although NDC 0338-3814-50 has Limited Availability with an estimated recovery date of December 2026. Sandoz Inc. offers 6 mg/mL, 12 mg/mL, and 18 mg/mL presentations in 5 percent dextrose listed as Available. Because individual package NDCs differ in stock status, each presentation must be evaluated independently.
Veterinarians sometimes use FDA-approved human drugs in their patients in an extra-label manner. Therefore, shortages of human drugs can affect veterinary medicine.
Vetinuity supports treatment options with citations and dose math.
Track veterinary and human drug shortages using FDA Center for Veterinary Medicine tables and CDER records.
FDA lists human-labeled dexmedetomidine injection in shortage, while Dexdomitor provides 0.1 mg/mL and 0.5 mg/mL veterinary formulations.
FDA lists human-labeled dextrose injection in shortage, with various concentrations showing available, limited, or unavailable supply.
FDA shortage status by lidocaine injection presentation, plus lidocaine and bupivacaine onset and duration for local blocks in dogs and cats.
Manufacturing delays and product discontinuations affect specific NDC presentations differently. Pfizer Inc. Cleocin Phosphate vials are Unavailable due to manufacturing delays with manufacturer-estimated recovery in December 2028, whereas Baxter Healthcare and Sandoz Inc. maintain several presentations listed as Available.
Estimated recovery dates provided in FDA records, such as Pfizer's estimated December 2028 recovery, represent manufacturer estimates rather than guaranteed supply return dates. These timelines may shift based on manufacturing and distribution updates.
As of 2026-11-08, clindamycin is absent from the FDA CVM animal drug shortage table. This does not establish product availability.
Vetinuity explains clinical options with journal citations.
The veterinarian diagnoses and prescribes.